Morbidity and Mortality Weekly Report (MMWR): Recommendations and Reports / Vol. 68 / No. 3, August 23, 2019

Details

• Alternative Title:
  Prevention and Control of Seasonal Influenza with Vaccines : Recommendations of the Advisory Committee on Immunization Practices — United States, 2019–20 Influenza Season
• Journal Article:
  Morbidity and Mortality Weekly Report (MMWR): Recommendations and Reports
• Personal Author:
  Grohskopf, Lisa A. ; Alyanak, Elif ; Broder, Karen R. ; Walter, Emmanuel B. ; Fry, Alicia M. ; Jernigan, Daniel B.
• Corporate Authors:
  United States. Advisory Committee on Immunization Practices. ; National Center for Immunization and Respiratory Diseases (U.S.). Influenza Division.
• Description:
  This report updates the 2018–19 recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding the use of seasonal influenza vaccines in the United States (MMWR Recomm Rep 2018;67No. RR-3). Routine annual influenza vaccination is recommended for all persons aged ≥6 months who do not have contraindications. A licensed, recommended, and age-appropriate vaccine should be used. Inactivated influenza vaccines (IIVs), recombinant influenza vaccine (RIV), and live attenuated influenza vaccine (LAIV) are expected to be available for the 2019–20 season. Standard-dose, unadjuvanted, inactivated influenza vaccines will be available in quadrivalent formulations (IIV4s). High-dose (HD-IIV3) and adjuvanted (aIIV3) inactivated influenza vaccines will be available in trivalent formulations. Recombinant (RIV4) and live attenuated influenza vaccine (LAIV4) will be available in quadrivalent formulations. ; Updates to the recommendations described in this report reflect discussions during public meetings of ACIP held on October 25, 2018; February 27, 2019; and June 27, 2019. Primary updates in this report include the following two items. First, 2019–20 U.S. trivalent influenza vaccines will contain hemagglutinin (HA) derived from an A/Brisbane/02/2018 (H1N1)pdm09–like virus, an A/Kansas/14/2017 (H3N2)–like virus, and a B/Colorado/06/2017–like virus (Victoria lineage). Quadrivalent influenza vaccines will contain HA derived from these three viruses, and a B/Phuket/3073/2013–like virus (Yamagata lineage). Second, recent labeling changes for two IIV4s, Afluria Quadrivalent and Fluzone Quadrivalent, are discussed. The age indication for Afluria Quadrivalent has been expanded from ≥5 years to ≥6 months. The dose volume for Afluria Quadrivalent is 0.25 mL for children aged 6 through 35 months and 0.5 mL for all persons aged ≥36 months (≥3 years). The dose volume for Fluzone Quadrivalent for children aged 6 through 35 months, which was previously 0.25 mL, is now either 0.25 mL or 0.5 mL. The dose volume for Fluzone Quadrivalent is 0.5 mL for all persons aged ≥36 months (≥3 years). ; This report focuses on the recommendations for use of vaccines for the prevention and control of influenza during the 2019–20 season in the United States. A brief summary of these recommendations and a Background Document containing additional information are available at https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/flu.html. These recommendations apply to U.S.-licensed influenza vaccines used within Food and Drug Administration–licensed indications. Updates and other information are available from CDC’s influenza website (https://www.cdc.gov/flu). Vaccination and health care providers should check this site periodically for additional information. ; Suggested citation for this article: Grohskopf LA, Alyanak E, Broder KR, Walter EB, Fry AM, Jernigan DB. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2019–20 Influenza Season. MMWR Recomm Rep 2019;68(No. RR-3):1–21. DOI: http://dx.doi.org/10.15585/mmwr.rr6803a1
• Subjects:
  • Adolescent
  • Adult
  • Aged
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Immunization Schedule
  • Infant
  • Influenza Vaccines / adverse effects
  More +
• Source:
  Morbidity and Mortality Weekly Report (MMWR): Recommendations and Reports, 2019; v. 68, no. 3
• Series:
  Recommendations and Reports: Morbidity and Mortality Weekly Report (MMWR)
• DOI:
  http://dx.doi.org/10.15585/mmwr.rr6803a1
• ISSN:
  1057-5987 (print) ; 1545-8601 (digital)
• Document Type:
  Text
• Genre:
  Journal Issue
• Place as Subject:
  United States
• Location:
  North America
• Pages in Document:
  28 pdf pages
• Volume:
  68
• Issue:
  3
• Download URL:
  https://stacks.cdc.gov/view/cdc/80811/cdc_80811_DS1.pdf
• File Type:
  [PDF - 772.61 KB]
• Collection(s):
  Morbidity and Mortality Weekly Report (MMWR) ; Advisory Committee on Immunization Practices (ACIP)
• Main Document Checksum:
  urn:sha-512:a0949d57ca4cfcf09b10941e270560ba8312d13e9eae9c7b845600ecb6a65135924f3689ef27c97e9d0e7e3c81f8ad165eaffc0316435b6627e7319db7a35e7e